Can Cancer Cause a Stroke? The Connection Explained

Cancer roughly doubles the risk of stroke compared to the general population, and certain cancers push that risk even higher. A large analysis of more than seven million cancer patients found that their rate of fatal stroke was about twice what would be expected in people without cancer, a gap that actually widened over time rather than closing.¹ The connection runs through several distinct pathways, from the cancer itself driving blood clots to the treatments used to fight it damaging blood vessels. Understanding which cancers carry the highest stroke risk, how cancer-related strokes look different on brain imaging, and why anticoagulation choices get complicated in these patients matters for anyone living with a cancer diagnosis or caring for someone who is.

How Much Does Cancer Raise Stroke Risk

The size of the risk depends on the type of cancer and how recently it was diagnosed. In a study matching over 327,000 cancer patients to controls without cancer, the three-month stroke rate after a lung cancer diagnosis was about 5.1%, compared to 1.2% in matched controls. Pancreatic cancer showed a similar gap, with a 3.4% stroke rate versus 1.3% in controls. Colorectal cancer patients had a 3.3% rate versus 1.3%.² Breast and prostate cancers carried smaller excess risks. These elevated rates were most pronounced in the first few months after diagnosis, fading over the following year in many cancers.

For fatal stroke specifically, the picture is grimmer when you zoom out. Across all cancer types, the standardized mortality ratio for stroke was about 2.17, meaning cancer patients were more than twice as likely to die of a stroke as the general population. That ratio actually climbed with time: beyond ten years after diagnosis, it reached nearly 2.9.¹ This long-term trend likely reflects the lasting vascular damage caused by cancer treatments like radiation and certain chemotherapy drugs, a subject addressed further below.

Why Cancer Makes Blood Clot When It Should Not

The most important mechanism linking cancer to stroke is a state of abnormal clotting called cancer-associated hypercoagulability. Tumors, particularly adenocarcinomas of the lung, pancreas, and gastrointestinal tract, release substances that activate the clotting cascade. Tissue factor, mucins, and inflammatory cytokines shed by tumor cells push the blood into a pro-clotting state that can produce both venous and arterial clots.³ When clots form in arteries supplying the brain or travel there from the heart, the result is ischemic stroke.

This phenomenon is sometimes called Trousseau syndrome, named after the 19th-century French physician who first described migratory blood clots in cancer patients. A particularly sobering case report describes a patient who suffered a stroke that turned out to be the first sign of hidden metastatic pancreatic cancer. Even after being placed on blood thinners, the patient developed recurrent strokes on both sides of the brain, illustrating how aggressive cancer-driven clotting can be.⁴

Hypercoagulability is not the only route. Cancer can also produce stroke through several other mechanisms:

• Non-bacterial thrombotic endocarditis (NBTE): Tiny sterile growths form on heart valves in patients with advanced cancer, then break off and travel to the brain. NBTE is considered an underdiagnosed cause of embolic stroke in cancer patients, particularly in those with disseminated disease and adenocarcinoma.⁵
• Paradoxical embolism: In patients who have a patent foramen ovale, a small hole between the heart’s upper chambers that persists from fetal development, a clot that forms in the veins can cross into the arterial circulation and reach the brain. Cancer increases the risk of venous clots, so patients with both cancer and a patent foramen ovale face a compounded threat. In one small case series, paradoxical embolism was judged the likely stroke mechanism in nearly half of cancer patients who had this heart defect, and the underlying venous clots were often silent until screening revealed them.⁶
• Direct tumor effects: Tumors inside the skull can compress arteries, and tumors growing in or near the heart can act as a source of embolism.³
• Hyperviscosity: Blood cancers like multiple myeloma can flood the blood with abnormal proteins, thickening it to the point where it sludges through small vessels. A documented case of IgG myeloma presented with a stroke caused by serum hyperviscosity as the first sign of the disease.⁷

Infections are worth mentioning too, because people undergoing chemotherapy have weakened immune systems and are vulnerable to infections that can inflame blood vessels or promote clotting. But the dominant pathway, the one that explains most cancer-related strokes, remains the hypercoagulable state driven by the tumor itself.

Which Cancers Carry the Highest Stroke Risk

Pancreatic cancer sits at the top. A systematic review and meta-analysis of studies in cancer survivors found that pancreatic cancer was associated with a roughly threefold increase in ischemic stroke risk and a roughly twofold increase in hemorrhagic stroke risk. Lung cancer was close behind, with about a 2.3-fold higher risk of ischemic stroke and a twofold higher risk of hemorrhagic stroke. Head and neck cancers showed a particularly elevated risk of hemorrhagic stroke, roughly 1.5 times higher than expected.⁸

Beyond these leaders, significantly increased stroke rates have also been documented in colorectal cancer, breast cancer, ovarian cancer, nasopharyngeal cancer, leukemia, and myeloma.⁸ In children and young adults, blood cancers are the most commonly associated with stroke. In adults, the link is strongest with adenocarcinomas, the type of cancer that arises in glandular tissue found in the lung, pancreas, colon, and stomach.⁹

The general pattern is that cancers known for aggressive biology and widespread metastasis tend to carry the highest stroke risk. Metastatic disease appears to amplify the hypercoagulable state, flooding the bloodstream with more tumor-derived pro-clotting signals. That said, even cancers typically considered more indolent, like prostate cancer, show some elevation in stroke risk during the early months after diagnosis, though the excess is much smaller and may not reach statistical significance for all stroke types.

When Cancer Treatment Itself Causes Strokes

Not all cancer-related strokes come from the tumor. Some are side effects of the treatments used to fight it, and these treatment-related strokes can appear years or even decades after therapy ends.

Radiation therapy aimed at the head and neck region is the most thoroughly studied example. Radiation damages the lining of carotid arteries, accelerating atherosclerosis, a thickening and narrowing of the vessel wall that can eventually restrict blood flow to the brain or give rise to clots. A comprehensive review found that radiation increased carotid artery wall thickness by roughly 18 to 40% and that patients treated with head and neck radiation faced up to a 5.6-fold higher relative risk of stroke compared to the general population.¹⁰ Even breast cancer patients who received radiation had a modestly elevated stroke risk, though the increase was much smaller because the radiation field is farther from the neck arteries.¹⁰

The damage happens on two fronts: radiation injures the inner lining of the artery, which speeds up plaque formation, and it harms the tiny blood vessels that supply the artery wall itself, compounding the injury.¹¹ Because this is a slow-building vascular disease, the stroke risk from radiation does not peak immediately. It often emerges years later, which means long-term cancer survivors need ongoing monitoring of their carotid arteries, especially if they received neck radiation at a young age.

Certain cancer drugs also raise stroke risk. Bevacizumab, an anti-angiogenesis drug that blocks the growth of new blood vessels to starve tumors, was associated with about a 44% higher risk of arterial blood clots, including strokes, in a meta-analysis of randomized trials.¹² Other drug classes with vascular side effects include certain hormone therapies and some newer immunotherapies, though the evidence base for stroke specifically is thinner for those agents.

How Doctors Recognize a Cancer-Related Stroke

Cancer-related strokes often look different on brain imaging than strokes caused by more conventional risk factors like atrial fibrillation or clogged arteries. The key distinguishing feature is a pattern of damage scattered across multiple vascular territories in the brain simultaneously, rather than confined to a single artery’s supply zone.

Researchers have described what they call the “Three Territory Sign”: acute areas of restricted blood flow visible on brain MRI that involve both sides of the brain and both the front and back circulation. This pattern was six times more common in strokes caused by cancer compared to strokes caused by atrial fibrillation, appearing in about 23% of malignancy-related strokes versus only 3.5% of those linked to atrial fibrillation.¹³ The individual areas of damage tend to be small, scattered, and located near the brain’s surface, rather than appearing as one large area of dead tissue.¹⁴

Blood tests provide a second critical clue. D-dimer, a protein fragment produced when blood clots break down, tends to be dramatically elevated in cancer-related strokes. A meta-analysis found that D-dimer levels were significantly higher in stroke patients with cancer compared to stroke patients without cancer.¹⁵ The combination of high D-dimer and the multi-territory imaging pattern is a reliable diagnostic pairing. Both D-dimer levels and the brain imaging pattern have proven to be good independent indicators of a cancer-related cause.¹⁶ D-dimer measurement can also help predict the risk of recurrent stroke and guide treatment decisions in these patients.¹⁷

When a Stroke Reveals Hidden Cancer

Sometimes the stroke comes first, and the cancer is discovered only afterward. In one study of 631 patients hospitalized for acute ischemic stroke, about 2.1% were found to have an occult malignancy. That figure jumped to 5.3% among patients whose stroke had no other identifiable cause.¹⁸ The strokes that raise the most suspicion for an underlying hidden cancer are those with both elevated D-dimer and damage scattered across multiple brain regions. In one investigation, a targeted workup for hidden cancer in ten patients showing this combination revealed malignancies in every single case.¹⁹

Case reports drive this point home vividly. A 37-year-old woman developed sudden vision loss during a coughing episode. Brain imaging showed multiple small strokes across different areas, and further workup revealed a pulmonary embolism, a patent foramen ovale, and, ultimately, an ovarian tumor that was compressing a vein and promoting clots. Her stroke was essentially the first domino that led to a cancer diagnosis.²⁰ Clinicians increasingly recognize that a stroke without a clear conventional cause, especially in a relatively young person with high D-dimer and multi-territory infarcts, warrants a cancer screening workup.

Managing Blood Clots When Cancer Is in the Picture

Treating and preventing clots in cancer patients is substantially more complicated than in the general population. The standard blood thinners used to prevent stroke do not all perform equally well in the setting of active cancer, and the clotting drive in these patients can overwhelm conventional doses.

For venous clots in cancer patients, injectable low-molecular-weight heparin (LMWH) has long been the preferred approach. More recently, direct oral anticoagulants (DOACs) have been studied as a more convenient alternative and have shown they can reduce recurrent venous clots with a manageable bleeding profile in many cancer patients.²¹ However, when the specific outcome of interest is ischemic stroke prevention rather than venous clot prevention, the picture shifts. A study comparing anticoagulants in cancer patients with venous blood clots found that DOAC-treated patients had a six-month stroke rate of about 6.8%, versus roughly 5% for those on LMWH or warfarin. DOACs were associated with a 36% higher odds of ischemic stroke compared to LMWH in this population.²²

This result is somewhat counterintuitive, because DOACs are generally effective stroke preventers in other settings. The issue may relate to the unique clotting mechanisms in cancer, where the shower of pro-coagulant signals from tumors may respond differently to the specific clotting factors that DOACs target versus those that heparin targets. Clinicians managing cancer-associated stroke have to weigh these trade-offs on a patient-by-patient basis, considering the cancer type, the extent of disease, and the patient’s bleeding risk.

Can Cancer Patients Still Receive Emergency Stroke Treatments

A common concern is whether cancer disqualifies someone from the clot-busting drugs and mechanical clot-removal procedures used in acute stroke emergencies. The answer, based on current evidence, is reassuring: cancer alone should not be an automatic exclusion.

A meta-analysis examining intravenous clot-busting therapy in cancer patients found no significant difference in outcomes between cancer and non-cancer patients in terms of favorable recovery, bleeding complications, or mortality. The authors concluded that cancer should not be treated as an exclusion criterion for this treatment.²³ Similarly, a study of mechanical clot removal found that cancer patients achieved comparable rates of vessel reopening and functional recovery at three months, with no significant difference in mortality from non-cancer patients. The one caveat was a significantly higher rate of bleeding transformation on brain imaging in the cancer group, though none of these bleeding events produced symptoms.²⁴

This is good news, but it comes with a practical wrinkle. Cancer-related strokes caused by the hypercoagulable state rather than a single large clot can be harder to treat with standard methods, because the underlying clotting tendency remains active even after one clot is dissolved or pulled out. That persistent drive helps explain why recurrence rates are higher in cancer patients and why long-term anticoagulation, rather than a one-time intervention, is central to management.

Outcomes After a Cancer-Related Stroke

Having cancer at the time of a stroke does worsen the prognosis. A large Japanese stroke registry study found that ischemic stroke patients with cancer had a lower rate of good functional outcomes, about 47.5% versus 56.3% for those without cancer. In-hospital mortality was also higher: roughly 6.7% compared to 4.5%.²⁵ These differences persisted even after adjusting for age, stroke severity, and other health conditions, suggesting that cancer itself and its associated complications genuinely contribute to worse recovery.

Part of the explanation is the tendency for cancer-related strokes to recur. The underlying pro-clotting state does not resolve until the cancer is treated or goes into remission, so patients remain at elevated risk for additional strokes even while on blood thinners. The interplay between active cancer treatment and stroke rehabilitation also creates challenges: chemotherapy can cause fatigue and immune suppression that complicate recovery, and the physical demands of rehabilitation compete with the energy costs of cancer therapy.

Ethical Complexity in Advanced Cancer and Acute Stroke

One of the harder questions that arises in clinical practice is what to do when a patient with advanced, terminal cancer suffers an acute stroke. Emergency stroke treatments like mechanical clot removal can restore blood flow and preserve brain function, but if the patient’s cancer is expected to be fatal within weeks or months, the benefit equation changes. Clinicians, patients, and families may grapple with whether an aggressive neurological intervention aligns with the patient’s goals of care, especially if the patient has already transitioned toward comfort-focused treatment. Little formal guidance exists to help navigate these decisions, and each case tends to involve a deeply individual conversation about quality of life, prognosis, and what recovery would realistically look like in the context of advanced illness.²⁶ These conversations are becoming more common as cancer patients live longer with metastatic disease thanks to newer therapies, increasing the window of time during which a stroke can occur.